Could a pill shield hearts from chemo damage? new study investigates

NCT ID NCT05256745

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called azeliragon can reduce heart damage caused by chemotherapy in women with early-stage breast cancer. About 48 participants will receive azeliragon alongside their standard chemo to see if it is safe and helps protect the heart and thinking abilities. The goal is to make cancer treatment safer without interfering with its effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER RELATED COGNITIVE DECLINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Georgetown Lombardi Comprehensive Cancer Center
RECRUITING

Washington D.C., District of Columbia, 20007, United States
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Medstar Washington Hospital Center
RECRUITING

Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.